Search
  • Erkim Public Relations

Aeterna Zentaris & Er-Kim Announce Partnership to Commercialize Macrilen in Eight European Countries

Updated: Mar 7

Istanbul, Turkey – January 31, 2022 – Er-Kim, a regional specialty pharmaceutical company, announced today the signature of an exclusive agreement with Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, for the distribution and sales of MacrilenTM (macrimorelin) in eight European countries outside the European Economic Area (EEA).

Under the terms of the agreement, Er-Kim will be exclusively responsible for the commercialization and distribution of MacrilenTM in eight countries, including Albania, Bosnia and Herzegovina, Kosovo, Moldova, Montenegro, Northern Macedonia, Serbia, and Turkey.

“We are delighted to partner with Er-KIM and expand the reach of macimorelin in the global markets. This partnership unlocks further economic potential and enables a substantial number of additional patients access to this innovative diagnostic test for Growth Hormone deficiency (GHD),” commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris.

Cem Zorlular, CEO of Er-Kim added; “We are delighted to announce our partnership with Aeterna Zentaris and to add macrimorelin to our growing endocrinology portfolio. Through our flexible commercialization platform, we are proud to be able to deliver this important product to 104 million additional patients in Europe while providing a significant additional market opportunity to our partner.”

About Aeterna Zentaris Inc. Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (MacrilenTM), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk. Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and chlamydia. For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

About Er-Kim Pharmaceuticals Er-Kim broadens and accelerates global patient access to innovative treatments by offering biopharmaceutical companies of all sizes flexible, sustainable, and compelling business models tocommercialize their products in international markets. Over the past forty years, more than sixty global pharmaceutical companies trusted Er-Kim as their regional partner. To learn more, please visit www.er- kim.com.

Contact Didem Yıldız – d.yildiz@er-kim.com

93 views0 comments